Navigation Links
Uroplasty Appoints Brett Reynolds As Chief Financial Officer
Date:8/12/2013

MINNEAPOLIS, Aug. 12, 2013 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced the appointment of Brett A. Reynolds as Senior Vice President and Chief Financial Officer. He joins Uroplasty following 10 years in senior positions, including Chief Financial Officer, with Synovis Life Technologies, a Twin Cities based medical device manufacturer acquired by Baxter International last year. 

"Brett's significant industry operational experience and proven public company financial leadership will be a valuable asset to Uroplasty.  His track record of building strong financial organizations and processes expands the depth of our executive leadership team and we are delighted to have him on board in this key role," said Rob Kill, President & CEO of Uroplasty.

Mr. Reynolds experience spans more than 20 years in finance and operations.  He was most recently the CFO of Synovis, staying on with the company as Site Leader following its sale to Baxter International in February 2012 for $325 million. Prior to Synovis, Mr. Reynolds served in executive financial positions at Chiquita Processed Foods, Arthur Andersen and Deloitte & Touche.

Mr. Reynolds is a Certified Public Accountant and holds a BA in Accounting and an MBA from the University of Minnesota's Carlson School of Management.

About Uroplasty, Inc.

Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom is a global medical company committed to offering transformative treatment options to specialty physicians.  Our products are designed to help providers change the lives of their voiding dysfunction patients and strengthen the efficiency of their practices. Our focus is the continued commercialization of our Urgent® PC Neuromodulation System, the only FDA-cleared system that delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence. We also offer Macroplastique®, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.

Forward-Looking Information
This press release contains forward-looking statements that reflect our best estimates regarding future events and financial performance.  These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our anticipated results.  We discuss in detail the factors that may affect the achievement of our forward-looking statements in our Annual Report on Form 10-K filed with the SEC.

For Further Information:
Uroplasty, Inc.
Rob Kill, President and CEO
952.426.6151

EVC Group
Jenifer Kirtland (Investors)/Janine McCargo (Business Media)
415.568.9349/646.688.0245


'/>"/>
SOURCE Uroplasty, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Uroplasty to Present at the 11th Annual JMP Securities Research Conference
2. Uroplasty Announces Product Development and New Clinical Trial Initiatives
3. Uroplasty Reports Fiscal Fourth Quarter And Full Year 2012 Financial Results
4. Uroplasty To Present At The JMP Securities Healthcare Conference
5. Uroplasty to Issue First Quarter of Fiscal 2013 Financial Results on July 26, 2012
6. Uroplasty Reports Fiscal First Quarter 2013 Financial Results
7. Uroplasty To Participate In Two Upcoming Conferences
8. Uroplasty Reports Fiscal Second Quarter 2013 Financial Results
9. Uroplasty To Participate In Two Upcoming Investor Conferences
10. Uroplasty To Participate In The Oppenheimer 23rd Annual Healthcare Conference
11. Uroplasty Reports Fiscal Third Quarter 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... -- Research and Markets has announced the addition of ... report to their offering. ... The report provides separate comprehensive analytics for the US, Canada ... Asia-Pacific , Latin America , and ... 2015 through 2022. Also, a six-year historic analysis is provided for these ...
(Date:3/24/2017)... , March 24, 2017  Eli Lilly ... announced plans to invest $850 million in its ... facilities across its U.S. enterprise, including research laboratories, ... investments are being driven by demand for Lilly ... potential medicines in development targeting cancer, pain, diabetes ...
(Date:3/24/2017)... , March 23, 2017  Mirabilis Medical, ... advanced medical technology for non-invasive surgery, announced today ... System for treatment of uterine fibroids throughout the ... had received approval from the US Food and ... the Mirabilis System in the United States.  The ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... Gastro Health ... partnership to prep patients for colonoscopy at the HyGIeaCare® Center that is to ... Miami, FL. , The HyGIeaCare® Prep, cleared by the U.S. Food ...
(Date:3/24/2017)... ... 2017 , ... “Finding Christ Through Social Media: Year One ... the writer’s path toward true communion with God. “Finding Christ Through Social Media: ... creation of published author Lea Michelle Johnson, a follower of Christ, wife and ...
(Date:3/24/2017)... ... March 24, 2017 , ... “The Communion of ... people of God in congregations across the United States. “The Communion of ... in 1964 who has served congregations in seven states throughout his long career ...
(Date:3/23/2017)... ... 23, 2017 , ... A recent report from the National Council on Teacher ... NCTQ report suggests, based on a review of GPA and SAT/ACT requirements at 221 ... the U.S. It argues that this higher bar should be set by states, by ...
(Date:3/23/2017)... ... March 23, 2017 , ... Texas Physical Therapy Specialists (TexPTS) ... Road in Building 2. The clinic is the group’s second in New Braunfels and ... the company’s second New Braunfels location brings things full circle for the group, “It’s ...
Breaking Medicine News(10 mins):